Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) EBITDA (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of EBITDA readings, the most recent being -$9.3 million for Q4 2024.

  • On a quarterly basis, EBITDA fell 46.7% to -$9.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$32.1 million, a 54.59% decrease, with the full-year FY2025 number at -$26.6 million, up 27.7% from a year prior.
  • EBITDA hit -$9.3 million in Q4 2024 for Unicycive Therapeutics, down from -$6.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$3.5 million in Q1 2022 to a low of -$9.3 million in Q4 2024.
  • Median EBITDA over the past 3 years was -$5.7 million (2022), compared with a mean of -$5.9 million.
  • The widest YoY moves for EBITDA: up 5.27% in 2024, down 119.04% in 2024.
  • Unicycive Therapeutics' EBITDA stood at -$5.3 million in 2022, then dropped by 18.55% to -$6.3 million in 2023, then crashed by 46.7% to -$9.3 million in 2024.
  • The last three reported values for EBITDA were -$9.3 million (Q4 2024), -$6.3 million (Q3 2024), and -$7.4 million (Q2 2024) per Business Quant data.